MAPK11
ENSG00000185386
Target class
Kinase
Chromosome
22
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- Yes
- Target name
- MAPK11
- Gene name
- Mitogen-activated protein kinase 11
- Gene symbol
- MAPK11
- Previous gene symbols
- PRKM11
- Protein name
- Mitogen-activated protein kinase 11 (MAP kinase 11) (MAPK 11) (EC 2.7.11.24) (Mitogen-activated protein kinase p38 beta) (MAP kinase p38 beta) (p38b) (Stress-activated protein kinase 2b) (SAPK2b) (p38-2)
- p38-2
- p38Beta
- SAPK2
- Gene biotype
- Protein coding
- Gene family
- Mitogen-activated protein kinases
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 105.53
- Tissue specificity (Gini)
- 0.404
- Tissue specificity (tau)
- 0.752
- KEGG gene identifiers
- hsa:5600
- Protein interaction confidence
- 0.877707
- Protein interaction partners
- 99
- R-HSA-168638
- R-HSA-171007
- R-HSA-198753
- R-HSA-2151209
- R-HSA-2559580
- R-HSA-4420097
- R-HSA-450302
- R-HSA-450341
- R-HSA-450604
- R-HSA-525793
- R-HSA-5668599
- R-HSA-6804756
- R-HSA-69601
- End position
- 50270767
- Start position
- 50263713
- Chromosome
- 22
- Strand
- Reverse
- Cytoplasm . Nucleus .
- Cytosol
- Tissue specificity (tau)
- 0.751792
- Expression inequality (Gini)
- 0.40435
Expression in transcripts per million
- Brain - Cerebellum
- 105.53
- Brain - Cerebellar Hemisphere
- 93.82
- Brain - Cortex
- 82.2
- Brain - Frontal Cortex (BA9)
- 71.45
- Brain - Anterior cingulate cortex (BA24)
- 55.5
Expression in transcripts per million
- Brain - Cerebellum105.53
- Brain - Cerebellar Hemisphere93.82
- Brain - Cortex82.2
- Brain - Frontal Cortex (BA9)71.45
- Brain - Anterior cingulate cortex (BA24)55.5
- Pituitary52.59
- Adipose - Visceral (Omentum)43.84
- Uterus43.55
- Breast - Mammary Tissue42.22
- Adipose - Subcutaneous41.24
- Brain - Caudate (basal ganglia)41.02
- Cervix - Endocervix40.6
- Brain - Nucleus accumbens (basal ganglia)39.27
- Cervix - Ectocervix38.39
- Fallopian Tube36.36
- Brain - Putamen (basal ganglia)35.01
- Prostate34.94
- Lung32.41
- Nerve - Tibial31.98
- Brain - Amygdala31.73
- Spleen26.49
- Kidney - Medulla26.25
- Ovary25.57
- Brain - Hippocampus25.35
- Brain - Hypothalamus25.28
And 29 more, listed on the interactive page.
- GO:0010628
- GO:0031098
- GO:0032735
- GO:0038066
- GO:0045648
- GO:0051149
- GO:0051403
- GO:0071347
- GO:0071493
- GO:0090398
- GO:0098586
- GO:0005654
- GO:0005829
- GO:0004674
- GO:0004707
- GO:0005515
- GO:0106310
regulation of catalytic activity
Studies
- biochemical: NVS_ENZ_hMAPK11, is one of one assay component(s) measured or calculated from the NVS_ENZ_hMAPK11 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.
Biological samples
- cell-free
Evidence source
Related records
Trials (416)
- "Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"
- (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
- [18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib
- [18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial
- [18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma
- [68 Ga]-DOTANOC PET/CT in GEP-NETs
- [68Ga]Ga-FAPI-46 in Staging of Head and Neck Carcinomas
- [68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation
- 11C-methionine in Diagnostics and Management of Glioblastoma Multiforme Patients (GlioMET)
- 18F-DCFBC PET/CT in Prostate Cancer
- 18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer
- 5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
- 68Ga-NODAGA-RGD PET/ CT for Tumoral Neoangiogenesis
- 68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC.
- 68Ga-NYM096/177Lu-NYM096 in Metastatic ccRCC
- 68Ga-PSMA PET/CT in Prostate Cancer
- 68Ga-PSMA PET/CT in Prostate Cancer
- 68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Intermediate Risk Prostate Cancer Imaging
- 68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Prostate Cancer Imaging According to Various Metastatic Risks
- 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study
Drugs (3)
- Losmapimod MAP kinase p38 beta inhibitor
- Regorafenib MAP kinase p38 beta inhibitor
- RWJ-67657 MAP kinase p38 beta inhibitor